WCLC 2025 - Posters & ePosters-P3.13.22 Efficacy and Safety of Surufatinib, Durvalumab in Combined With Chemotherapy as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

P3.13.22 Efficacy and Safety of Surufatinib, Durvalumab in Combined With Chemotherapy as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Back to course

Pdf Summary

This study evaluates the efficacy and safety of surufatinib combined with durvalumab and platinum-based chemotherapy (etoposide plus cisplatin or carboplatin) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC). Surufatinib is a multi-kinase inhibitor targeting VEGFR, FGFR, and CSF1R, with potential synergistic effects when combined with immunotherapy. This ongoing single-arm, multicenter, open-label trial (NCT05668767) enrolled 13 eligible patients by March 2025, with a median follow-up of 13.4 months.<br /><br />Patients were adults with confirmed ES-SCLC, measurable lesions, ECOG performance status 0-1, no prior systemic therapy, and no or asymptomatic brain metastases. Treatment involved surufatinib 250 mg daily, durvalumab 1500 mg IV every 3 weeks, along with standard etoposide and platinum chemotherapy every 3 weeks for 4-6 cycles, followed by surufatinib plus durvalumab maintenance for those achieving disease control.<br /><br />Results showed a median overall survival (mOS) of 15.8 months and median progression-free survival (mPFS) of 7.95 months. The objective response rate (ORR) was 100%, with all 11 evaluable patients achieving partial responses and a disease control rate (DCR) of 100%. Median duration of response was 5.22 months, with a median time to response of 1.58 months.<br /><br />Adverse events (AEs) were manageable and mostly hematologic: white blood cell decrease (61.54%), anemia (46.15%), and platelet decrease (38.46%). Grade 3 AEs included white blood cell decrease (46.15%) and platelet decrease (15.38%), fatigue (7.69%), and immune-related pneumonia (7.69%).<br /><br />The study suggests that combining chemotherapy, immunotherapy, and anti-angiogenesis therapy with surufatinib and durvalumab shows promising efficacy and manageable toxicity as 1L treatment for ES-SCLC, warranting further investigation.

Asset Subtitle

Ying Hu

Meta Tag

Speaker Ying Hu

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

surufatinib

durvalumab

platinum-based chemotherapy

extensive-stage small-cell lung cancer

first-line treatment

multi-kinase inhibitor

VEGFR

FGFR

CSF1R

immunotherapy